ML Bio Solutions was formally founded in 2018, yet the company’s founders have been dedicated to finding a cure for LGMD2i for close to twenty years, an endeavor that started as a love story.
In 2001, Hugh L. McColl, Jr. learned that his granddaughter had been diagnosed with LGMD2i. Approached by Dr. Jeffrey Rosenfeld at Carolinas Medical Center (now Atrium Health) in 2002 about funding research to find a cure for LGMD2i, McColl, after consulting with his wife Jane, his daughter Jane McColl Lockwood, and son-in-law Luther Lockwood, enthusiastically committed a major gift to start this critical research to honor the love of his family.
A global search for talented researchers led to hiring Dr. Qi Long Lu, M.D., Ph.D., who in 2018 published the seminal data that would provide the foundation for ML Bio Solutions. In that paper, Dr. Lu and his team demonstrated that a prodrug based on sugar – BBP-418 – overcomes the inefficiencies in the mutated FKRP gene. ML Bio Solutions was founded based upon that research, and the hope that it gives that a treatment for LGMD2i may be available in the near future.
The McColl-Lockwood family is still actively involved with the McColl-Lockwood Lab and ML Bio Solutions, with Luther Lockwood serving as the company’s founding board chairman and president. The little girl who inspired our founding, Jane B. Lockwood, is not unlike the thousands of other patients suffering from LGMD2i, all of whom we are hoping to quickly, safely and effectively treat with the advancement of BBP-418.